Crystal Research Associates has released a new Executive Informational Overview (EIO) on MetaStat, Inc. (MTST-OTC). This comprehensive, 68-page document updates an earlier EIO published on MetaStat in January 2013. The Company has achieved several significant milestones over the past year and a half, which are each detailed in the new EIO along with current product development and market descriptions for MetaStat’s diagnostic and therapeutic programs.

1. .
• An updated 68‐page
Executive Informational Overview® (EIO)
written by Crystal Research Associates on
MetaStat, Inc. (MTST) is available at
www.crystalra.com.
• Report covers a range of topics:
o Oncology markets
o MTST’s diagnostic and therapeutic product
development: MetaSite Breast, MenaCalc, and
MenaBloc
o MTST’s novel approach centering on the Mena
protein and its alternatively spliced isoforms
o Competition
o …and other key fundamentals
Crystal Research Associates Presents:
New Independent Equity Research
Published April 23, 2014

2. .
• Crystal Research Associates’ Executive Informational Overview® (EIO)
presents a crystal clear, comprehensive report on a company in a manner
that is easily understood by the Wall Street financial community
• Details a company’s product/technology/service offerings, market size(s),
key intellectual property, leadership, growth strategy, competition, risks,
financial statements, key events, and other fundamental information.
• Free of investment ratings, target prices, and forward‐looking financial
models
• Complete risks and disclosures included in each EIO
• Trademarked EIOs are exclusively written by experienced, award‐winning
analysts at Crystal Research Associates
What is an EIO?

3. .
Overview of MetaStat, Inc. (MTST)
• A life sciences company commercializing a new approach to reliably determine a patient’s
individual risk of developing systemic metastatic cancer, and then to help reduce this risk
through active intervention of the metastatic process
• Portfolio includes two diagnostic platforms targeting breast, prostate, lung, and colorectal
cancers, which could enter the market as early as 2015, as well as a therapeutic program:
• MetaSite Breast is a clinical laboratory assay (or test) to predict the likelihood of an
early‐stage breast cancer patient’s tumor spreading to distant body parts
• MenaCalc is a diagnostic technology platform for use in determining individual levels
of variants of the Mena protein (called “Mena isoforms”) in cancer tissue. Mena has at
least five isoforms, and measuring the relationship between these variants can help
create an individual metastatic profile as early on in disease progression as possible.
• MenaBloc therapeutics may ultimately prevent metastasis among high‐risk patients
when administered as a maintenance therapy after surgery or in conjunction with
chemotherapy and other targeted therapies.

4. .
MetaStat Product Roadmap: Commercialization
Path in 2015 and Beyond

5. .
Technology Introduction
• In most individuals, the Mena protein is only present in developing embryos where the protein supports
nervous system branching. Mena becomes scarce and undetectable in healthy adults.
• However, Mena also appears in cancer cells, where it supports cancer invasion and metastasis by enabling
cancer cells to invade surrounding tissues and migrate toward and penetrate blood vessels.
The key discovery forming the foundation for MetaStat’s product candidates is that the Mena protein
isoforms (variants) are important regulators of the metastatic cascade.

6. .
Target Indications for Improving Metastatic Risk Stratification
• MetaSite Breast and MenaCalc
Breast diagnostics could provide
metastatic risk coverage to the
entire breast cancer market
• ~ 225,000 new Stage 0‐3
breast cancer diagnoses/yr
• Prostate cancer could also
become a major market for
MetaStat
• 93% of all prostate cancers
are in the local or regional
stages at diagnosis—
representing over 220,000
people each year who
could benefit from an
improved measure of their
risk of developing
metastatic prostate cancer

7. .
New Developments Described in Report
• Initial sales and marketing plans for MetaSite Breast, which is anticipated to commence sales in
2015
• MetaStat’s December 2013 presentation of results from a large‐scale study of its MetaSite Breast
test at the San Antonio Breast Cancer Symposium
• Results of a clinical validation of the MenaCalc technology presented at the 2014 Annual Meeting
of the U.S. and Canadian Academy of Pathology
• The October 2013 opening of a drug discovery laboratory in affiliation with Stony Brook University
• Recent license agreements with MIT and other institutions for the use of alternatively spliced
mRNA and protein isoform markers in the diagnosis, prognosis, and treatment of metastatic,
epithelial‐based solid tumors—which is central to the Company’s ongoing MenaBloc therapeutic
development
• Additions to executive leadership that include a former senior executive from Roche as MetaStat’s
new Head of Diagnostics
• Establishment of a highly skilled Scientific Advisory Board for Therapeutics
• Current patent position and strategies
• Most recent historical financial position and fundraising goals

8. .
• Highly experienced—CEO and CMO Dr. Oscar L. Bronsther is a diplomat, American Board of
Surgery; chairman, Section of General Surgery, at Inova Fairfax Hospital; and clinical professor of
surgery at George Washington University in Washington, D.C.
• MetaStat’s Head of Diagnostics Dr. Heiner Dreismann comes to the company from Roche, where
he was president and CEO of Roche Molecular Systems, head of global business development for
Roche Diagnostics, and member of Roche’s Global Diagnostic Executive Committee
o Scientific Advisory Board for Therapeutics includes individuals from Duke University and the
Duke‐NUS Medical School, the Dana‐Farber Cancer Institute, the Cold Spring Harbor
Laboratory, and MIT
o Scientific Advisory Board for Diagnostics includes individuals from the Department of
Anatomy and Structural Biology and the Department of Epidemiology and Population Health
at the Albert Einstein College of Medicine, and the Koch Institute for Integrative Cancer
Research at MIT
o Clinical Advisory Board includes an attending pathologist at New York Presbyterian Hospital
and a professor of medicine and women’s health at the Albert Einstein College of Medicine
• The Board of Directors has considerable business acumen, and includes the CEO of FluoroPharma
Medical Inc., the president and CEO of Frontier Airlines, Inc., and the CEO and chairman of Echo
Therapeutics, Inc.
Management

9. .
To read the entire 68‐page EIO on
MetaStat, Inc. (MTST)
or find information on other companies under
coverage, please visit www.crystalra.com.

10. .
Crystal Research Associates, LLC (www.crystalra.com) is an independent research firm that has
provided institutional‐quality research on small‐ and mid‐cap companies for the past decade. We
are led by veteran Wall Street sell‐side analyst Jeffrey Kraws, who is well known by the
international financial media for his years of work on Wall Street and for providing consistent
award‐winning analyses and developing long‐term relationships on both the buy‐side and sell‐
side. He has been consistently ranked among the Top Ten Analysts for pharmaceutical stock
performance in the world for almost two decades as well as ranked as the Number One Stock
Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally,
Mr. Kraws has been 5‐Star ranked for top biotechnology stock performance by Starmine.
About Us
Corporate Headquarters:
880 Third Avenue, 6th Floor
New York, NY 10022
Office: (212) 851‐6685
Fax: (609) 395‐9339
Satellite Office Location:
2500 Quantum Lakes Drive, Suite 203
Boynton Beach, FL 33426
Office: (561) 542‐6903
Fax: (561) 853‐2246
Jeffrey J. Kraws,
Chief Executive Officer
Karen B. Goldfarb
President & COO

11. .
FACEBOOK — https://www.facebook.com/CrystalResearchAssociates
TWITTER — http://twitter.com/crystalresearch
YOUTUBE — https://www.youtube.com/user/crystalrsch
LINKEDIN — http://www.linkedin.com/company/crystal‐research‐associates
SLIDESHARE — http://www.slideshare.net/crystalresearchassociates
Connect with Crystal Research Associates